Nurix Therapeutics, Inc. (NRIX)

Nurix Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is December - November.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	55.53	65.38	80.79	119.53	34.99
Short-Term Investments	233.28	244.67	215.21	161.79	2.9
Cash & Cash Equivalents	288.81	310.04	296.01	281.32	37.89
Cash Growth	-6.85%	4.74%	5.22%	642.46%	-3.36%
Receivables	0	0	6	0	0
Other Current Assets	6.69	8.41	9.11	17.12	1.46
Total Current Assets	295.5	318.45	311.12	298.43	39.35
Property, Plant & Equipment	47.95	29.51	25.35	6.67	3.87
Long-Term Investments	7.42	63.88	137.19	90.89	0.51
Other Long-Term Assets	4.72	4.92	3.12	0.35	0.32
Total Long-Term Assets	60.1	98.31	165.65	97.91	4.69
Total Assets	355.6	416.76	476.77	396.34	44.05
Accounts Payable	6.4	5.06	6.65	3.41	1.6
Deferred Revenue	93.12	73.61	100.23	93.48	45.31
Current Debt	7.49	5.53	3.85	0	0
Other Current Liabilities	-20.05	-13.55	-44.47	-52.36	-30.77
Total Current Liabilities	86.96	70.66	66.26	44.54	16.14
Long-Term Debt	23.13	6.43	9.19	0	0
Other Long-Term Liabilities	45.02	35.97	59.02	61.54	37.43
Total Long-Term Liabilities	68.15	42.41	68.21	61.54	37.43
Total Liabilities	155.11	113.06	134.47	106.07	53.57
Total Debt	30.61	11.96	13.04	0	0
Debt Growth	155.88%	-8.22%	-	-	-
Retained Earnings	-545.2	-401.25	-220.89	-103.7	-60.46
Comprehensive Income	-0.66	-4.32	-0.61	0.09	-0
Shareholders' Equity	200.49	303.7	342.3	290.27	-57.71
Net Cash / Debt	258.2	298.08	282.97	281.32	37.89
Net Cash / Debt Growth	-13.38%	5.34%	0.59%	642.46%	-3.36%
Net Cash Per Share	4.75	6.13	6.60	17.95	11.51
Working Capital	208.55	247.79	244.86	253.9	23.22
Book Value Per Share	3.69	6.25	7.98	18.52	-17.53

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).